Biorez, Inc., a clinical stage regenerative medicine company in New Haven, Connecticut, recently announced a new scientific advisory board of anterior cruciate ligament (ACL) experts, including many internationally renowned researchers, surgeons and leaders in sports medicine and medical device development.
ACL Experts Join Biorez Scientific Advisory Board
2 min read Premium comments
Secondary
According to a press release, Biorez is currently involved in its second round of preclinical animal studies on its proprietary tissue-engineered bioresorbable scaffold designed to be used in anterior cruciate ligament reconstruction surgery to regenerate ACL tissue in vivo. The new scientific advisory board will help guide the company as they move to getting regulatory approvals for a human clinical study.
“We are extremely pleased to announce the formalization of our relationship with these distinguished individuals, each of whom already contributed significantly to the ongoing development of our technology,” Kevin Rocco, Biorez CEO said in the release.
“This team has the diverse depth of expertise needed to reinvent ACL reconstruction, and we are grateful for their support and guidance.”
The new scientific advisory board includes:
Robert A. Arciero, M. D., professor and chief of the Sports Medicine Division of the Department of Orthopaedic at the University of Connecticut Health Center, is a former president of the American Orthopaedic Society of Sports Medicine and is a recipient of the prestigious George D. Rovere Award for his contributions in education.
Steven Arnoczky, DVM, DACVS, DACVSMR, professor emeritus at the Small Animal Clinical Sciences Laboratory for Comparative Orthopedics Research at the College of Veterinary Medicine at Michigan State University, was the first Wade O. Brinker Endowed Professor of Surgery at Michigan State. He was also inducted into the American Orthopaedic Society for Sports Medicine’s Hall of Fame (AOSSM) in 2014.
Dale R. Peterson, Ph. D., chief science officer at HemaFlo Therapeutics, Inc., in San Diego, California, has commercialized 19 medical products and holds 24 U.S. patents in a variety of fields, including stem cells, new resorbable polymers, protein chemistry, growth factors, medical textiles, diagnostics, cell biology, and new biocompatible adhesives.
Robert A. Stanton, M. D., is a former president of the American Orthopaedic Society for Sports Medicine and is currently a clinical instructor of orthopedic surgery at Yale University School of Medicine. He is also senior attending physician at Bridgeport Hospital.
Bill Walsh, Ph. D., professor and director of the Surgical & Orthopaedic Research Laboratories at the Prince of Wales Clinical School of the University of South Wales, Sydney, Australia, has conducted his own research on the interface between implanted materials and the connective tissues of the body as it relates to orthopedic, plastic and reconstructive and vascular surgery.
Arnoczky said in the release, “I am very excited to join the Biorez team. The company has made considerable progress with its technology over the past few years, and I look forward to helping guide the future development of this promising technology.”
Stanton also added, “Surgeons in sports medicine have been searching for a faster, better, and less invasive approach to ACL reconstruction for some time. The Biorez platform may well prove to be the world’s first synthetic ACL graft that fully remodels into new functional tissue.”
For more information, visit http://biorez.com/.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.